Similar articles

• [Pleiotropic effects of statins].

  Palomäki A. Palomäki A. Duodecim. 2004;120(4):411-8. Duodecim. 2004. PMID: 15065459 Review. Finnish. No abstract available.
• Statins and cancer risk: decrease or increase?

  Goldstein MR, Mascitelli L, Pezzetta F. Goldstein MR, et al. Am J Med. 2008 Sep;121(9):e17, author reply e19. doi: 10.1016/j.amjmed.2008.04.019. Am J Med. 2008. PMID: 18724946 No abstract available.
• [Is there a risk to discontinue statin treatment? Statins are advantageous also to the elderly].

  Savolainen M. Savolainen M. Duodecim. 2004;120(8):909-10. Duodecim. 2004. PMID: 15185502 Finnish. No abstract available.
• [To give or not to give? Towards the indication of CSE inhibitors ("statins")].

  Teichert M, Lüer AK, Stichtenoth DO. Teichert M, et al. Med Monatsschr Pharm. 2008 May;31(5):184-5. Med Monatsschr Pharm. 2008. PMID: 18552075 German.
• Mechanisms of disease: HDL metabolism as a target for novel therapies.

  Rader DJ. Rader DJ. Nat Clin Pract Cardiovasc Med. 2007 Feb;4(2):102-9. doi: 10.1038/ncpcardio0768. Nat Clin Pract Cardiovasc Med. 2007. PMID: 17245404 Review.